Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06605118 · ClinicalTrials.gov registry record · Phase 3

Azithromycin Prophylaxis for PRElabor CEsarean DElivery Trial

A Phase 3 study of Cesarean Delivery and Obstetrical Complications, sponsored by The George Washington University Biostatistics Center.

Recruiting
Registry status
Phase 3
Development phase
8,000
Enrollment target
14
Study locations

NCT06605118: Recruiting Phase 3 study of Cesarean Delivery and Obstetrical Complications, sponsored by The George Washington University Biostatistics Center.

NCT06605118 is a Phase 3 study of Cesarean Delivery and Obstetrical Complications that is actively recruiting participants, run by The George Washington University Biostatistics Center. The registered enrollment target is 8,000 participants, above the 2,683-participant average among 10 other Cesarean Delivery trials with a reported enrollment target (198% higher). The trial reports 14 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06605118, a Phase 3 study of Cesarean Delivery and Obstetrical Complications, is actively recruiting participants, sponsored by The George Washington University Biostatistics Center.

RECRUITING
Registry status
Phase 3
Development phase
8,000 participants
Enrollment target
14
Study locations

Study Summary

This is a phase-III multi-center double-blind randomized controlled trial of 8,000 individuals undergoing a scheduled or prelabor cesarean delivery who are randomized to either adjunctive azithromycin prophylaxis or to placebo. Both groups also will receive standard of care preoperative antibiotics (excluding azithromycin). The primary endpoint is a maternal infection composite defined as any one of the following up to 6 weeks postpartum: endometritis, wound infection, abscess, septic thrombosis, sepsis, pneumonia, pyelonephritis and breast infection.

Primary Outcome

a maternal infection composite defined as any one of the following: endometritis, wound infection, abdominal or pelvic abscess, septic pelvic thrombosis, sepsis, pneumonia, pyelonephritis and breast infection

Interventions

  • DRUG Placebo
  • DRUG Azithromycin Injection
  • DRUG Standard of Care Preoperative antibiotics

Study Locations (14)

North Carolina

  • University of North Carolina - Chapel Hill - Chapel Hill
  • Duke University - Durham

Ohio

  • Case Western Reserve University - Cleveland
  • Ohio State University - Columbus

Pennsylvania

  • Hospital of the University of Pennsylvania - Philadelphia
  • Magee Women's Hospital - Pittsburgh

Texas

  • Baylor College of Medicine - Houston
  • University of Texas - Houston - Houston

Alabama

  • University of Alabama - Birmingham - Birmingham

California

  • Regents of the University of California San Francisco - San Francisco

Illinois

  • Northwestern University - Chicago

New York

  • Columbia University - New York

Trial Details

FieldValue
Enrollment Target 8,000 participants
Start Date 2024-11-06
Est. Completion 2027-11-30
Phase Phase 3

What NCT06605118 shows while recruiting

NCT06605118 is an interventional study that assigns participants to a tested intervention. Its 8,000 participants enrollment target places it among the larger protocols in the corpus, above the 2,683-participant average among 10 other Cesarean Delivery trials with a reported enrollment target (198% higher).

The record links to 3 conditions, with Cesarean Delivery appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT06605118 lists 14 locations in 10 states (North Carolina, Ohio, Pennsylvania).

Frequently Asked Questions

What is clinical trial NCT06605118 about?

NCT06605118 is a clinical study titled "Azithromycin Prophylaxis for PRElabor CEsarean DElivery Trial". This is a phase-III multi-center double-blind randomized controlled trial of 8,000 individuals undergoing a scheduled or prelabor cesarean delivery who are randomized to either adjunctive azithromycin prophylaxis or to placebo. Both groups also will receive standard of care preoperative antibiotics ...

What is the current status of trial NCT06605118?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 8,000 participants. The study started on 2024-11-06. Estimated completion is 2027-11-30.

What conditions does trial NCT06605118 study?

This clinical trial studies the following conditions: Cesarean Delivery, Obstetrical Complications, Labor and Delivery Complication.

What interventions are being tested in trial NCT06605118?

The interventions under investigation include: Placebo (DRUG), Azithromycin Injection (DRUG), Standard of Care Preoperative antibiotics (DRUG).

Who is sponsoring clinical trial NCT06605118?

This trial is sponsored by The George Washington University Biostatistics Center, which has 24 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06605118 being conducted?

This trial has 14 study locations across Alabama, California, Illinois, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cesarean Delivery

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06605118's enrollment target sits among peer trials

8,000 2nd of 10 the highest of 10 other Cesarean Delivery trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cesarean Delivery trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00539162 · 8,000 participants · NA

    Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women

  • NCT00898638 · 8,000 participants

    Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants

  • NCT02240862 · 8,000 participants

    The CREST-2 Registry

  • NCT03072927 · 8,000 participants

    MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06605118, the US trial registry maintained by the National Library of Medicine. NCT06605118 (large enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.